Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies
Year: 2014
Type: review
Abstract: Tyrosine kinase inhibitors (TKIs) are at the forefront of molecular-targeted therapies for cancer. With the advent of imatinib for the treatment of chronic myelogenous leukemia, a new wave of small-molecule therapeutics redefined the oncologic treatment to become chronically administered medications with tolerable side-effect profiles compared with cytotoxic agents. Effects on bone mineral metabolism were observed during early imatinib treatment, in the form of hypophosphatemia with increased urinary phosphorus excretion. This finding led to detailed investigations of off-target effects responsible for changes in bone cell maturation, activity, and impact on bone mass. Subsequently, another BCR-Abl inhibitor (dasatinib), vascular endothelial growth factor (VEGF) inhibitors (sorafenib and sunitinib) as well as rearranged during transfection (RET) inhibitors (vandetanib and cabozantinib) were developed. Inhibition of bone resorption appears to be a class effect and is likely contributed by TKI effects on the hematopoietic and mesenchymal stem cells. As long-term, prospective, clinical outcomes data accumulate on these targeted therapies, the full extent of off-target side effects on bone health will need to be considered along with the significant benefits of tyrosine kinase inhibition in oncologic treatment.
Source: Endocrine Related Cancer
DOI: 10.1530/erc-12-0400
Authors: José O Alemán, Azeez Farooki, Monica Girotra
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: tyrosine kinase inhibitors, bone metabolism, off-target effects, imatinib, dasatinib, sorafenib, sunitinib, vandetanib, cabozantinib, BCR-ABL tyrosine kinase inhibitors, VEGF inhibitors, RET inhibitors, hypophosphatemia, bone resorption, bone mineral density, hematopoietic stem cells, mesenchymal stem cells, chronic myeloid leukemia, cancer treatment side effects
Open Access status: bronze
OpenAlex ID: W2122118178
